Physician profile
James P Gallagher
NPI 1720068927
$407.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $145 · 2021: $38.42 · 2022: $22.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.73 | 2019-2021 | |
| Allergan, INC. | $55.64 | 2019 | |
| Amarin Pharma, INC. | $55.49 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $49.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $30.00 | 2020 | |
| Kerecis Limited | $25.58 | 2019 | |
| Alkermes, INC. | $22.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $21.44 | 2021 | |
| Eisai INC. | $16.25 | 2020 | |
| Lilly USA, LLC | $11.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.